Direct administration of insulin-like growth factor to fetal rhesus monkeys (Macaca mulatta)

Alice F Tarantal, Maya K. Hunter, Sharron E. Gargosky

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

A potential treatment for the amelioration of fetal growth failure is insulin-like growth factor-I (IGF-I). To address concerns of safety and efficacy, IGF-I (80 μg/kg; GroPep Pty.) was administered ip to healthy rhesus monkey fetuses via ultrasound guidance every other day between gestational days (GD) 110-120 and 130-140 (third trimester; term = approximately GD 165 ± 10; n = 6). Pregnancies were monitored sonographically, and fetal/maternal blood samples were collected for complete blood counts, immunophenotyping, and biochemical analyses. Blood samples, external measures of the fetus and newborn, and tissue and organ weights were collected at fetal necropsy (GD 150; n = 2) or at term delivery of neonates (GD 160; n = 4). The results of these investigations have shown no evidence of hypoglycemia in the fetus or dam during the course of treatment. Circulating concentrations of fetal, but not maternal IGF-I increased with treatment (~80 to ~1015 ng/ml), and there was no evidence of a change in serum IGF-II or an increase in IGF binding protein-3 compared with historical control values. Fetal lymphocytes and select red cell parameters increased, and a significant elevation in circulating B cells and CD4/CD8 ratios in fetal lymph nodes was shown. Although no changes were detected in body weights, increases in thymic, splenic, and kidney weights and small intestine lengths occurred. Thus, administration of IGF-I to the fetal monkey is safe and results in 1) transient increases in circulating IGF-I, 2) a significant effect on fetal hematopoietic and lymphoid tissues, and 3) an increase in select fetal organ weights and measures. These data suggest that IGF-I may represent a potential candidate for therapeutic treatment of growth- compromised human fetuses in utero.

Original languageEnglish (US)
Pages (from-to)3349-3358
Number of pages10
JournalEndocrinology
Volume138
Issue number8
DOIs
StatePublished - 1997

Fingerprint

Somatomedins
Macaca mulatta
Insulin-Like Growth Factor I
Fetus
Organ Size
Mothers
Weights and Measures
Immunophenotyping
CD4-CD8 Ratio
Insulin-Like Growth Factor Binding Protein 3
Fetal Weight
Insulin-Like Growth Factor II
Blood Cell Count
Third Pregnancy Trimester
Lymphoid Tissue
Fetal Development
Fetal Blood
Hypoglycemia
Small Intestine
Haplorhini

ASJC Scopus subject areas

  • Endocrinology
  • Endocrinology, Diabetes and Metabolism

Cite this

Direct administration of insulin-like growth factor to fetal rhesus monkeys (Macaca mulatta). / Tarantal, Alice F; Hunter, Maya K.; Gargosky, Sharron E.

In: Endocrinology, Vol. 138, No. 8, 1997, p. 3349-3358.

Research output: Contribution to journalArticle

Tarantal, Alice F ; Hunter, Maya K. ; Gargosky, Sharron E. / Direct administration of insulin-like growth factor to fetal rhesus monkeys (Macaca mulatta). In: Endocrinology. 1997 ; Vol. 138, No. 8. pp. 3349-3358.
@article{8b61e37f2b3b4ab19a8d5a3180e969fb,
title = "Direct administration of insulin-like growth factor to fetal rhesus monkeys (Macaca mulatta)",
abstract = "A potential treatment for the amelioration of fetal growth failure is insulin-like growth factor-I (IGF-I). To address concerns of safety and efficacy, IGF-I (80 μg/kg; GroPep Pty.) was administered ip to healthy rhesus monkey fetuses via ultrasound guidance every other day between gestational days (GD) 110-120 and 130-140 (third trimester; term = approximately GD 165 ± 10; n = 6). Pregnancies were monitored sonographically, and fetal/maternal blood samples were collected for complete blood counts, immunophenotyping, and biochemical analyses. Blood samples, external measures of the fetus and newborn, and tissue and organ weights were collected at fetal necropsy (GD 150; n = 2) or at term delivery of neonates (GD 160; n = 4). The results of these investigations have shown no evidence of hypoglycemia in the fetus or dam during the course of treatment. Circulating concentrations of fetal, but not maternal IGF-I increased with treatment (~80 to ~1015 ng/ml), and there was no evidence of a change in serum IGF-II or an increase in IGF binding protein-3 compared with historical control values. Fetal lymphocytes and select red cell parameters increased, and a significant elevation in circulating B cells and CD4/CD8 ratios in fetal lymph nodes was shown. Although no changes were detected in body weights, increases in thymic, splenic, and kidney weights and small intestine lengths occurred. Thus, administration of IGF-I to the fetal monkey is safe and results in 1) transient increases in circulating IGF-I, 2) a significant effect on fetal hematopoietic and lymphoid tissues, and 3) an increase in select fetal organ weights and measures. These data suggest that IGF-I may represent a potential candidate for therapeutic treatment of growth- compromised human fetuses in utero.",
author = "Tarantal, {Alice F} and Hunter, {Maya K.} and Gargosky, {Sharron E.}",
year = "1997",
doi = "10.1210/en.138.8.3349",
language = "English (US)",
volume = "138",
pages = "3349--3358",
journal = "Endocrinology",
issn = "0013-7227",
publisher = "The Endocrine Society",
number = "8",

}

TY - JOUR

T1 - Direct administration of insulin-like growth factor to fetal rhesus monkeys (Macaca mulatta)

AU - Tarantal, Alice F

AU - Hunter, Maya K.

AU - Gargosky, Sharron E.

PY - 1997

Y1 - 1997

N2 - A potential treatment for the amelioration of fetal growth failure is insulin-like growth factor-I (IGF-I). To address concerns of safety and efficacy, IGF-I (80 μg/kg; GroPep Pty.) was administered ip to healthy rhesus monkey fetuses via ultrasound guidance every other day between gestational days (GD) 110-120 and 130-140 (third trimester; term = approximately GD 165 ± 10; n = 6). Pregnancies were monitored sonographically, and fetal/maternal blood samples were collected for complete blood counts, immunophenotyping, and biochemical analyses. Blood samples, external measures of the fetus and newborn, and tissue and organ weights were collected at fetal necropsy (GD 150; n = 2) or at term delivery of neonates (GD 160; n = 4). The results of these investigations have shown no evidence of hypoglycemia in the fetus or dam during the course of treatment. Circulating concentrations of fetal, but not maternal IGF-I increased with treatment (~80 to ~1015 ng/ml), and there was no evidence of a change in serum IGF-II or an increase in IGF binding protein-3 compared with historical control values. Fetal lymphocytes and select red cell parameters increased, and a significant elevation in circulating B cells and CD4/CD8 ratios in fetal lymph nodes was shown. Although no changes were detected in body weights, increases in thymic, splenic, and kidney weights and small intestine lengths occurred. Thus, administration of IGF-I to the fetal monkey is safe and results in 1) transient increases in circulating IGF-I, 2) a significant effect on fetal hematopoietic and lymphoid tissues, and 3) an increase in select fetal organ weights and measures. These data suggest that IGF-I may represent a potential candidate for therapeutic treatment of growth- compromised human fetuses in utero.

AB - A potential treatment for the amelioration of fetal growth failure is insulin-like growth factor-I (IGF-I). To address concerns of safety and efficacy, IGF-I (80 μg/kg; GroPep Pty.) was administered ip to healthy rhesus monkey fetuses via ultrasound guidance every other day between gestational days (GD) 110-120 and 130-140 (third trimester; term = approximately GD 165 ± 10; n = 6). Pregnancies were monitored sonographically, and fetal/maternal blood samples were collected for complete blood counts, immunophenotyping, and biochemical analyses. Blood samples, external measures of the fetus and newborn, and tissue and organ weights were collected at fetal necropsy (GD 150; n = 2) or at term delivery of neonates (GD 160; n = 4). The results of these investigations have shown no evidence of hypoglycemia in the fetus or dam during the course of treatment. Circulating concentrations of fetal, but not maternal IGF-I increased with treatment (~80 to ~1015 ng/ml), and there was no evidence of a change in serum IGF-II or an increase in IGF binding protein-3 compared with historical control values. Fetal lymphocytes and select red cell parameters increased, and a significant elevation in circulating B cells and CD4/CD8 ratios in fetal lymph nodes was shown. Although no changes were detected in body weights, increases in thymic, splenic, and kidney weights and small intestine lengths occurred. Thus, administration of IGF-I to the fetal monkey is safe and results in 1) transient increases in circulating IGF-I, 2) a significant effect on fetal hematopoietic and lymphoid tissues, and 3) an increase in select fetal organ weights and measures. These data suggest that IGF-I may represent a potential candidate for therapeutic treatment of growth- compromised human fetuses in utero.

UR - http://www.scopus.com/inward/record.url?scp=0030741033&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030741033&partnerID=8YFLogxK

U2 - 10.1210/en.138.8.3349

DO - 10.1210/en.138.8.3349

M3 - Article

C2 - 9231787

AN - SCOPUS:0030741033

VL - 138

SP - 3349

EP - 3358

JO - Endocrinology

JF - Endocrinology

SN - 0013-7227

IS - 8

ER -